Peter Kolchinsky Holdings 13F: Latest RA Capital Management Portfolio Changes
RA Capital Management. Healthcare/biotech hedge fund (~$9.8B AUM). Investment stage to commercial.
As of the latest Q2 2026 13F filing, Peter Kolchinsky (managing RA Capital Management) reported a public portfolio value of $11.5B with 84 positions. This page tracks latest holdings, latest 13F changes, top buys, top sells, and top holdings from the public filing. The top recent buy was ASND. The top recent sell was ASND.
Open interactive portfolioLatest 13F portfolio changes
Peter Kolchinsky holdings 13F summary: the latest RA Capital Management portfolio changes show top holdings including ASCENDIS PHARMA A/S, PARABILIS MEDICINES, RHYTHM PHARMACEUTICALS, VAXCYTE, and SIONNA THERAPEUTICS, reported top buys such as ASCENDIS PHARMA A/S, PARABILIS MEDICINES, HEMAB THERAPEUTICS HOLDINGS, and ARTIVA BIOTHERAPEUTICS, and top sells or reductions such as ASCENDIS PHARMA A/S - ADR, EDGEWISE THERAPEUTICS, DIANTHUS THERAPEUTICS, and GH RESEARCH.
Latest filing metadata: quarter Q2 2026; report date 2026-06-30; filing date 2026-08-14; disclosure source SEC 13F.
Peter Kolchinsky 13F portfolio and latest holdings overview
Peter Kolchinsky's Q2 2026 13F holdings show RA Capital Management reporting 84 positions with a disclosed portfolio value of $11.5B. For readers searching Peter Kolchinsky 13F holdings, Peter Kolchinsky portfolio, RA Capital Management holdings, or latest 13F changes, the latest top holdings include ASCENDIS PHARMA A/S, PARABILIS MEDICINES, RHYTHM PHARMACEUTICALS, VAXCYTE, and SIONNA THERAPEUTICS.
The three largest reported positions add up to roughly 37.1%, which helps readers judge portfolio concentration rather than just headline AUM. The largest reported sector exposure is Health Care at 79.3% of the disclosed portfolio. This makes the page useful for comparing the manager's actual disclosed exposure with market narratives around the same names.
The latest change data highlights reported buys such as ASCENDIS PHARMA A/S, PARABILIS MEDICINES, HEMAB THERAPEUTICS HOLDINGS, ARTIVA BIOTHERAPEUTICS, and ABIVAX SA-ADR and reported reductions or exits such as ASCENDIS PHARMA A/S - ADR, EDGEWISE THERAPEUTICS, DIANTHUS THERAPEUTICS, GH RESEARCH, and NUVALENT INC-A. Those changes should be read as historical disclosure signals, not as real-time trade alerts.
The filing metadata lists report date 2026-06-30, filing date 2026-08-14, SEC accession 0001104659-26-097251. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
Peter Kolchinsky portfolio analytics
the top five positions account for 46.7% of disclosed value; the largest sector exposure is Health Care at 79.3%; reported buy and sell activity implies roughly 80.5% turnover this period; cost-basis P&L across 83 tracked positions averages 166.5% (63/79 currently in profit).
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| ASND whale holders ASCENDIS PHARMA A/S | $2.74B | 23.8% | New |
| PBLS whale holders PARABILIS MEDICINES INC | $791.9M | 6.9% | New |
| RYTM whale holders RHYTHM PHARMACEUTICALS INC | $740.2M | 6.4% | Held |
| PCVX whale holders VAXCYTE INC | $667.0M | 5.8% | Held |
| SION whale holders SIONNA THERAPEUTICS INC | $435.7M | 3.8% | Held |
| TYRA whale holders TYRA BIOSCIENCES INC | $389.6M | 3.4% | Held |
| EWTX whale holders EDGEWISE THERAPEUTICS INC | $341.0M | 3.0% | Reduced |
| NAMSW whale holders NEWAMSTERDAM PHARMA CO NV | $323.7M | 2.8% | Held |
| COAG whale holders HEMAB THERAPEUTICS HOLDINGS | $286.8M | 2.5% | New |
| SEPN whale holders SEPTERNA INC | $234.3M | 2.0% | Held |
Top buys
- ASND whale holders — ASCENDIS PHARMA A/S ($2.74B)
- PBLS whale holders — PARABILIS MEDICINES INC ($791.9M)
- COAG whale holders — HEMAB THERAPEUTICS HOLDINGS ($286.8M)
- ARTV whale holders — ARTIVA BIOTHERAPEUTICS INC ($174.2M)
- AAVXF whale holders — ABIVAX SA-ADR ($150.9M)
- ORKA whale holders — ORUKA THERAPEUTICS INC ($148.0M)
Top sells
- ASND whale holders — ASCENDIS PHARMA A/S - ADR ($2.35B)
- EWTX whale holders — EDGEWISE THERAPEUTICS INC ($341.0M)
- DNTH whale holders — DIANTHUS THERAPEUTICS INC ($219.2M)
- GHRS whale holders — GH RESEARCH PLC ($205.3M)
- NUVL whale holders — NUVALENT INC-A ($153.9M)
- PRAX whale holders — PRAXIS PRECISION MEDICINES I ($120.4M)
Allocation
- Health Care: 79.3%
- Other: 20.4%
- Information Technology: 0.3%
- Financials: 0.1%
Data notes
Report date: 2026-06-30
Disclosure source: SEC 13F
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
- Joseph Edelman 13F holdings and Perceptive Advisors portfolio changes — Perceptive Advisors
- Tom Gayner 13F holdings and Markel Group portfolio changes — Markel Group
- George Soros 13F holdings and Soros Fund Management portfolio changes — Soros Fund Management
- Turtle Creek Asset Management 13F holdings and portfolio changes — Turtle Creek Asset Management
- Philippe Laffont 13F holdings and Coatue Management portfolio changes — Coatue Management
- Leopold Aschenbrenner 13F holdings and Situational Awareness LP portfolio changes — Situational Awareness LP
- Gavin Baker 13F holdings and Atreides Management portfolio changes — Atreides Management
- Edgewood Management 13F holdings and Edgewood Management LLC portfolio changes — Edgewood Management LLC
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Frequently asked questions
Peter Kolchinsky 13F Holdings
The Q2 2026 13F profile for Peter Kolchinsky and RA Capital Management shows 84 reported positions, $11.5B in disclosed portfolio value, and top holdings including ASCENDIS PHARMA A/S, PARABILIS MEDICINES, RHYTHM PHARMACEUTICALS, VAXCYTE, and SIONNA THERAPEUTICS.
What is Peter Kolchinsky buying? Latest 13F changes
The latest tracked change data for Peter Kolchinsky highlights reported buys such as ASCENDIS PHARMA A/S, PARABILIS MEDICINES, HEMAB THERAPEUTICS HOLDINGS, and ARTIVA BIOTHERAPEUTICS and reported sells or reductions such as ASCENDIS PHARMA A/S - ADR, EDGEWISE THERAPEUTICS, DIANTHUS THERAPEUTICS, and GH RESEARCH.
RA Capital Management top holdings
RA Capital Management top holdings are summarized from public disclosures with reported values, weights, portfolio concentration, top buys, top sells, and filing metadata where available.
Peter Kolchinsky buys and sells
Use the top buys and top sells sections above to compare Peter Kolchinsky's reported additions, reductions, exits, and latest portfolio activity against other tracked investors.
How delayed is Peter Kolchinsky's 13F data?
SEC Form 13F requires institutional investment managers with $100M+ in US equities to disclose their holdings quarterly. Read our comprehensive 13F guide for timing, coverage, and limitations. Read the Whale Analyzer 13F guide.